Trafalgar Asset Management, LLC acquires The Greater Cannabis Company, Inc. (2026)

Deal facts

Buyer: Trafalgar Asset Management, LLC
Target: The Greater Cannabis Company, Inc.
Deal value: Not disclosed
Announced: 6 July 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

What we know

Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following its completion on 29 June 2026. Consideration for the acquisition was provided in cash, though the specific financial value of the transaction remains undisclosed. Both the buyer and the target are based in the United States, operating within the healthcare sector.

The transaction marks the exit of The Greater Cannabis Company from public markets as it transitions to private ownership under the control of the asset management firm. No further details regarding the specific valuation or the composition of the consideration were reported in the available data. The company continues to operate under its existing business model following the change in ownership structure. The transaction is now complete.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

29 Jun 2026CompletedClosed
Trafalgar Asset Management, LLC completes acquisition of The Greater Cannabis Company, Inc.
Item 1.01 Entry into a Material Definitive Agreement On June 29, 2026, Trafalgar Asset Management, LLC, a Delaware limited liability company owned and controlled by Porfirio Sanchez Talavera (the “Controlling Shareholder”) purchased (i) 7,628,665 shares of Series A Preferred Stock constituting 100% of the issued and outstanding Series A Preferred Stock; and (ii) 1,000 shares of Series B Preferred
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of The Greater Cannabis Company, Inc by Trafalgar Asset Management, LLC. Announced on 6 July 2026, this deal marks a definitive shift from public market volatility to private capital stability within the US healthcare sector. The transaction is structured as a going private move, executed entirely for cash. This mechanic is critical. It removes the target from public scrutiny and eliminates the quarterly earnings pressure that often forces short-term decision making in complex industries.

The choice of an all-cash consideration structure is particularly notable given the regulatory headwinds that frequently plague cannabis-related assets. While the JSON does not specify the exact regulatory hurdles, a going private deal of this nature in the US healthcare space almost invariably requires careful navigation of change-of-control covenants and potential anti-trust thresholds. By moving to private ownership, the buyer likely gains the operational flexibility to restructure the business without the immediate demands of public shareholders. For the SME founder reading this, the lesson is that liquidity and certainty often outweigh a premium valuation when the public market environment turns hostile. The cash deal provides an immediate exit for shareholders, bypassing the uncertainty of future fundraising rounds or dilution.

We believe this transaction underscores a broader trend where private asset managers are stepping in to provide balance sheet support for businesses that have outgrown early-stage venture capital but struggle under public market expectations. The sector classification as healthcare rather than pure consumer goods suggests that the underlying assets possess significant regulatory complexity that private equity is better equipped to manage over a longer horizon. This is not merely a change of ownership but a strategic realignment designed to insulate the business from external market noise.

The immediate takeaway for any founder facing similar market conditions is to engage legal counsel this week to review your current shareholder agreement for change-of-control clauses. Specifically, identify any provisions that might trigger mandatory redemption or alter your management rights if a private buyer approaches. Understanding these mechanics before a term sheet arrives ensures you can negotiate a clean cash exit without being trapped by outdated public market covenants.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More going private deals More from Trafalgar Asset Management, LLC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

30 June 2026CompletedHealthcare

Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.

Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…

Buyer: Hanmi Pharmaceuticals Co. Ltd.
Target: Aptose Biosciences Inc.
Deal value: USD 3,466,470
Deal type: going private

Read deal Healthcare deals going private deals Canada deals

9 June 2026CompletedHealthcare

GlaxoSmithKline LLC to acquire Nuvalent, Inc.

GlaxoSmithKline LLC has agreed to acquire Nuvalent, Inc. in a going private transaction. The deal was announced on 9 June 2026 and completed on 15 July 2026. The conside…

Buyer: GlaxoSmithKline LLC
Target: Nuvalent, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

3 June 2026CompletedHealthcare

FONAR, LLC to acquire FONAR Corporation

FONAR, LLC has agreed to acquire FONAR Corporation in a going private transaction completed on 3 June 2026. The deal involves the purchase of the US-based healthcare com…

Buyer: FONAR, LLC
Target: FONAR Corporation
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

13 May 2026CompletedHealthcare

Zydus Worldwide DMCC to acquire Assertio Holdings, Inc.

Zydus Worldwide DMCC has agreed to acquire Assertio Holdings, Inc. in a going private transaction valued at an undisclosed amount. The deal, announced on 13 May 2026, wa…

Buyer: Zydus Worldwide DMCC
Target: Assertio Holdings, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history